Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection

Journal of Infectious Diseases

Volumn 211, Issue 4, 2015, Pages 600-612

  Schub, David ^a   Janssen, Eva ^a   Leyking, Sarah ^a   Sester, Urban ^a   Assmann, Gunter ^a   Hennes, Pia ^a   Smola, Sigrun ^a   Vogt, Thomas ^a   Rohrer, Tilman ^a   Sester, Martina ^a   Schmidt, Tina ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

cellular immunity; herpes zoster; shingles; T cells; varicella zoster virus; VZV

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; VIRUS ANTIBODY;

ADOLESCENCE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY SPECIFICITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CHILD; CLONAL ANERGY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INFANT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; BLOOD; CELL CULTURE; IMMUNOLOGY; MIDDLE AGED; PRESCHOOL CHILD; T LYMPHOCYTE; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; INFANT; MALE; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84922438550     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu500     Document Type: Article

References (36)

1. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70(suppl 1):S111-8.
2. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 2013; 81:928-30.
3. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4:108-15.
4. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364-71.
5. Pergam SA, Limaye AP, AST Infectious Diseases Community of Practice. Varicella zoster virus (VZV) in solid organ transplantation. Am J Transplant 2013; 13(suppl 4):138-46.
6. Palmer L, White RR, Johnson BH, Fowler R, Acosta CJ. Herpes zoster-attributable resource utilization and cost burden in patients with solid organ transplant. Transplantation 2014; 97:1178-84.
7. Gross G, Schofer H, Wassilew S, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003; 26:277-89; discussion 291-3.
8. Sauerbrei A, Eichhorn U, Schacke M, Wutzler P. Laboratory diagnosis of herpes zoster. J Clin Virol 1999; 14:31-6.
9. Doerr HW, Rentschler M, Scheifler G. Serologic detection of active infections with human herpes viruses (CMV, EBV, HSV, VZV): diagnostic potential of IgA class and IgG subclass-specific antibodies. Infection 1987; 15:93-8.
10. Sadaoka K, Okamoto S, Gomi Y, et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis 2008; 198:1327-33.
11. Malavige GN, Jones L, Black AP, Ogg GS. Rapid effector function of varicella-zoster virus glycoprotein I-specific CD4+ T cells many decades after primary infection. J Infect Dis 2007; 195:660-4.
12. Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW. Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus. J Infect Dis 2004; 190:72-82.
13. Park HB, Kim KC, Park JH, et al. Association of reduced CD4T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol 2004; 31:2151-5.
14. Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with vi-remia and reversible functional anergy. Am J Transplant 2008; 8:1486-97.
15. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-9.
16. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006; 211:236-54.
17. Sester U, Fousse M, Dirks J, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS One 2011; 6:e17813.
18. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96:333-60.
19. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? a TBNET consensus statement. Eur Respir J 2009; 33:956-73.
20. Robert-Koch-Institut. Begründung der STIKO für eine allgemeine Var-izellenimpfung. Epidemiol Bull 2004;49:421-3.
21. Girndt M, Sester M, Sester U, Kaul H, Kohler H. Molecular aspects of T-and B-cell function in uremia. Kidney Int Suppl 2001; 78:S206-11.
22. Girndt M, Sester U, Sester M, Kaul H, Kohler H. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999; 14:2807-10.
23. Kuo CC, Lee CT, Lee IM, Ho SC, Yang CY. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis 2012; 59:428-33.
24. Schmidt T, Adam C, Hirsch HH, et al. BK Polyomavirus-specific cellular immune responses are age-dependent and strongly correlate with phases of virus replication. Am J Transplant 2014; 14:1334-45.
25. Schmidt T, Sester M. Detection of antigen-specific T cells based on in-tracellular cytokine staining using flow-cytometry. Methods Mol Biol 2013; 1064:267-74.
26. Sester U, Gartner BC, Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5:1483-9.
27. Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis 2010; 201:1024-30.
28. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35.
29. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336-44.
30. Patterson-Bartlett J, Levin MJ, Lang N, Schodel FP, Vessey R, Weinberg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 2007; 25:7087-93.
31. Tang H, Moriishi E, Okamoto S, et al. A community-based survey of varicella-zoster virus-specific immune responses in the elderly. J Clin Virol 2012; 55:46-50.
32. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068-77.
33. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006; 6:417-23.
34. Schmidt T, Dirks J, Enders M, et al. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. Eur J Immunol 2012; 42:1755-66.
35. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005; 105:13-21.
36. Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8:1246-54.